Annual revenue:
$14.20B+$1.08B(+8.27%)Summary
- As of today (April 25, 2025), REGN annual revenue is $14.20 billion, with the most recent change of +$1.08 billion (+8.27%) on December 31, 2024.
- During the last 3 years, REGN annual revenue has fallen by -$1.87 billion (-11.63%).
- REGN annual revenue is now -11.63% below its all-time high of $16.07 billion, reached on December 31, 2021.
Performance
REGN Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly revenue:
$3.79B+$68.50M(+1.84%)Summary
- As of today (April 25, 2025), REGN quarterly revenue is $3.79 billion, with the most recent change of +$68.50 million (+1.84%) on December 31, 2024.
- Over the past year, REGN quarterly revenue has increased by +$354.90 million (+10.33%).
- REGN quarterly revenue is now -26.26% below its all-time high of $5.14 billion, reached on June 30, 2021.
Performance
REGN Quarterly revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM revenue:
$14.20B+$354.90M(+2.56%)Summary
- As of today (April 25, 2025), REGN TTM revenue is $14.20 billion, with the most recent change of +$354.90 million (+2.56%) on December 31, 2024.
- Over the past year, REGN TTM revenue has increased by +$1.08 billion (+8.27%).
- REGN TTM revenue is now -13.97% below its all-time high of $16.51 billion, reached on March 31, 2022.
Performance
REGN TTM revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
REGN Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.3% | +10.3% | +8.3% |
| 3 y3 years | -11.6% | +10.3% | +8.3% |
| 5 y5 years | +116.6% | +10.3% | +8.3% |
REGN Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -11.6% | +16.7% | at high | +32.6% | -14.0% | +16.7% |
| 5 y | 5-year | -11.6% | +116.6% | -26.3% | +107.3% | -14.0% | +102.5% |
| alltime | all time | -11.6% | >+9999.0% | -26.3% | >+9999.0% | -14.0% | >+9999.0% |
Regeneron Pharmaceuticals Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $14.20B(+8.3%) | $3.79B(+1.8%) | $14.20B(+2.6%) |
| Sep 2024 | - | $3.72B(+4.9%) | $13.85B(+2.7%) |
| Jun 2024 | - | $3.55B(+12.8%) | $13.49B(+3.0%) |
| Mar 2024 | - | $3.15B(-8.4%) | $13.10B(-0.1%) |
| Dec 2023 | $13.12B(+7.8%) | $3.43B(+2.1%) | $13.12B(+0.2%) |
| Sep 2023 | - | $3.36B(+6.5%) | $13.10B(+3.4%) |
| Jun 2023 | - | $3.16B(-0.1%) | $12.67B(+2.4%) |
| Mar 2023 | - | $3.16B(-7.4%) | $12.37B(+1.6%) |
| Dec 2022 | $12.17B(-24.3%) | $3.41B(+16.3%) | $12.17B(-11.2%) |
| Sep 2022 | - | $2.94B(+2.8%) | $13.71B(-3.6%) |
| Jun 2022 | - | $2.86B(-3.6%) | $14.23B(-13.8%) |
| Mar 2022 | - | $2.97B(-40.1%) | $16.51B(+2.7%) |
| Dec 2021 | $16.07B(+89.1%) | $4.95B(+43.4%) | $16.07B(+18.7%) |
| Sep 2021 | - | $3.45B(-32.8%) | $13.54B(+9.4%) |
| Jun 2021 | - | $5.14B(+103.2%) | $12.38B(+34.6%) |
| Mar 2021 | - | $2.53B(+4.4%) | $9.20B(+8.2%) |
| Dec 2020 | $8.50B(+29.6%) | $2.42B(+5.6%) | $8.50B(+7.0%) |
| Sep 2020 | - | $2.29B(+17.5%) | $7.94B(+7.4%) |
| Jun 2020 | - | $1.95B(+6.8%) | $7.39B(+5.3%) |
| Mar 2020 | - | $1.83B(-1.9%) | $7.01B(+6.9%) |
| Dec 2019 | $6.56B(+27.4%) | $1.86B(+6.9%) | $6.56B(+29.7%) |
| Sep 2019 | - | $1.74B(+10.5%) | $5.06B(+1.6%) |
| Jun 2019 | - | $1.58B(+14.9%) | $4.98B(-0.6%) |
| Mar 2019 | - | $1.37B(+278.5%) | $5.01B(-2.7%) |
| Dec 2018 | $5.15B(-12.4%) | $362.60M(-78.2%) | $5.15B(-19.2%) |
| Sep 2018 | - | $1.66B(+3.5%) | $6.37B(+2.6%) |
| Jun 2018 | - | $1.61B(+6.4%) | $6.20B(+2.3%) |
| Mar 2018 | - | $1.51B(-4.5%) | $6.06B(+3.3%) |
| Dec 2017 | $5.87B(+20.8%) | $1.58B(+5.4%) | $5.87B(+6.4%) |
| Sep 2017 | - | $1.50B(+2.1%) | $5.52B(+5.4%) |
| Jun 2017 | - | $1.47B(+11.5%) | $5.24B(+5.2%) |
| Mar 2017 | - | $1.32B(+7.5%) | $4.98B(+2.4%) |
| Dec 2016 | $4.86B(+18.4%) | $1.23B(+0.5%) | $4.86B(+2.7%) |
| Sep 2016 | - | $1.22B(+0.6%) | $4.73B(+1.8%) |
| Jun 2016 | - | $1.21B(+1.0%) | $4.65B(+4.8%) |
| Mar 2016 | - | $1.20B(+9.4%) | $4.43B(+8.1%) |
| Dec 2015 | $4.10B(+45.5%) | $1.10B(-3.5%) | $4.10B(+7.8%) |
| Sep 2015 | - | $1.14B(+13.9%) | $3.81B(+12.1%) |
| Jun 2015 | - | $998.62M(+14.8%) | $3.40B(+10.9%) |
| Mar 2015 | - | $869.61M(+8.4%) | $3.06B(+8.6%) |
| Dec 2014 | $2.82B(+34.0%) | $802.33M(+10.5%) | $2.82B(+7.3%) |
| Sep 2014 | - | $725.79M(+9.0%) | $2.63B(+5.2%) |
| Jun 2014 | - | $665.70M(+6.4%) | $2.50B(+9.1%) |
| Mar 2014 | - | $625.74M(+2.5%) | $2.29B(+8.8%) |
| Dec 2013 | $2.10B(+52.7%) | $610.41M(+2.2%) | $2.10B(+10.3%) |
| Sep 2013 | - | $597.03M(+30.5%) | $1.91B(+9.7%) |
| Jun 2013 | - | $457.64M(+4.1%) | $1.74B(+9.7%) |
| Mar 2013 | - | $439.66M(+6.0%) | $1.59B(+15.1%) |
| Dec 2012 | $1.38B(+209.2%) | $414.60M(-3.1%) | $1.38B(+26.8%) |
| Sep 2012 | - | $427.69M(+40.5%) | $1.09B(+42.6%) |
| Jun 2012 | - | $304.40M(+31.3%) | $762.00M(+34.8%) |
| Mar 2012 | - | $231.79M(+88.5%) | $565.41M(+26.8%) |
| Dec 2011 | $445.82M(-2.9%) | $122.98M(+19.6%) | $445.82M(-2.3%) |
| Sep 2011 | - | $102.83M(-4.6%) | $456.52M(-0.7%) |
| Jun 2011 | - | $107.81M(-3.9%) | $459.67M(-1.7%) |
| Mar 2011 | - | $112.20M(-16.1%) | $467.74M(+1.9%) |
| Dec 2010 | $459.07M(+21.0%) | $133.68M(+26.1%) | $459.07M(+8.7%) |
| Sep 2010 | - | $105.98M(-8.5%) | $422.20M(-2.6%) |
| Jun 2010 | - | $115.89M(+11.9%) | $433.68M(+6.3%) |
| Mar 2010 | - | $103.53M(+7.0%) | $407.82M(+7.5%) |
| Dec 2009 | $379.27M(+59.1%) | $96.80M(-17.6%) | $379.27M(+12.1%) |
| Sep 2009 | - | $117.45M(+30.5%) | $338.31M(+18.1%) |
| Jun 2009 | - | $90.03M(+20.1%) | $286.43M(+11.4%) |
| Mar 2009 | - | $74.98M(+34.3%) | $257.06M(+7.8%) |
| Dec 2008 | $238.46M(+90.7%) | $55.84M(-14.9%) | $238.46M(-3.6%) |
| Sep 2008 | - | $65.58M(+8.1%) | $247.35M(+21.2%) |
| Jun 2008 | - | $60.65M(+7.6%) | $204.08M(+23.2%) |
| Mar 2008 | - | $56.38M(-12.9%) | $165.62M(+32.5%) |
| Dec 2007 | $125.02M | $64.73M(+190.1%) | $125.02M(+77.0%) |
| Sep 2007 | - | $22.31M(+0.5%) | $70.64M(+10.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2007 | - | $22.20M(+40.6%) | $63.95M(+4.8%) |
| Mar 2007 | - | $15.79M(+52.6%) | $61.02M(-3.8%) |
| Dec 2006 | $63.45M(-4.1%) | $10.35M(-33.8%) | $63.45M(-10.0%) |
| Sep 2006 | - | $15.62M(-18.9%) | $70.53M(-0.8%) |
| Jun 2006 | - | $19.26M(+5.7%) | $71.09M(+4.2%) |
| Mar 2006 | - | $18.22M(+4.6%) | $68.20M(+3.0%) |
| Dec 2005 | $66.19M(-62.0%) | $17.42M(+7.6%) | $66.19M(-30.9%) |
| Sep 2005 | - | $16.19M(-1.1%) | $95.86M(-17.5%) |
| Jun 2005 | - | $16.37M(+1.0%) | $116.18M(-9.4%) |
| Mar 2005 | - | $16.21M(-65.6%) | $128.24M(-26.3%) |
| Dec 2004 | $174.02M(+202.7%) | $47.09M(+28.9%) | $174.02M(+17.4%) |
| Sep 2004 | - | $36.52M(+28.5%) | $148.20M(+14.8%) |
| Jun 2004 | - | $28.42M(-54.2%) | $129.07M(+17.8%) |
| Mar 2004 | - | $61.99M(+191.4%) | $109.56M(+89.9%) |
| Dec 2003 | $57.50M(+161.5%) | $21.27M(+22.3%) | $57.71M(+39.6%) |
| Sep 2003 | - | $17.39M(+95.2%) | $41.35M(+35.5%) |
| Jun 2003 | - | $8.91M(-12.1%) | $30.52M(+12.3%) |
| Mar 2003 | - | $10.14M(+106.4%) | $27.18M(+23.6%) |
| Dec 2002 | $21.99M(+0.1%) | $4.91M(-25.2%) | $21.99M(+2.4%) |
| Sep 2002 | - | $6.57M(+17.9%) | $21.48M(+5.3%) |
| Jun 2002 | - | $5.57M(+12.7%) | $20.39M(-1.0%) |
| Mar 2002 | - | $4.94M(+12.3%) | $20.60M(-6.2%) |
| Dec 2001 | $21.97M(-62.9%) | $4.40M(-19.7%) | $21.97M(-40.1%) |
| Sep 2001 | - | $5.48M(-5.2%) | $36.71M(-20.6%) |
| Jun 2001 | - | $5.78M(-8.5%) | $46.23M(-15.9%) |
| Mar 2001 | - | $6.31M(-67.0%) | $55.00M(-7.1%) |
| Dec 2000 | $59.28M(+71.8%) | $19.14M(+27.6%) | $59.18M(+13.9%) |
| Sep 2000 | - | $15.00M(+3.1%) | $51.95M(+7.7%) |
| Jun 2000 | - | $14.55M(+38.6%) | $48.25M(+21.8%) |
| Mar 2000 | - | $10.50M(-11.8%) | $39.60M(+14.8%) |
| Dec 1999 | $34.50M(-9.9%) | $11.90M(+5.3%) | $34.50M(+14.2%) |
| Sep 1999 | - | $11.30M(+91.5%) | $30.20M(+1.7%) |
| Jun 1999 | - | $5.90M(+9.3%) | $29.70M(-20.4%) |
| Mar 1999 | - | $5.40M(-28.9%) | $37.30M(-2.9%) |
| Dec 1998 | $38.30M(+42.4%) | $7.60M(-29.6%) | $38.40M(+6.7%) |
| Sep 1998 | - | $10.80M(-20.0%) | $36.00M(+5.6%) |
| Jun 1998 | - | $13.50M(+107.7%) | $34.10M(+25.4%) |
| Mar 1998 | - | $6.50M(+25.0%) | $27.20M(+1.1%) |
| Dec 1997 | $26.90M(+11.6%) | $5.20M(-41.6%) | $26.90M(-4.6%) |
| Sep 1997 | - | $8.90M(+34.8%) | $28.20M(+10.6%) |
| Jun 1997 | - | $6.60M(+6.5%) | $25.50M(+1.6%) |
| Mar 1997 | - | $6.20M(-4.6%) | $25.10M(+4.1%) |
| Dec 1996 | $24.10M(-12.0%) | $6.50M(+4.8%) | $24.10M(+3.0%) |
| Sep 1996 | - | $6.20M(0.0%) | $23.40M(0.0%) |
| Jun 1996 | - | $6.20M(+19.2%) | $23.40M(-5.6%) |
| Mar 1996 | - | $5.20M(-10.3%) | $24.80M(-6.4%) |
| Dec 1995 | $27.40M(+18.1%) | $5.80M(-6.5%) | $26.50M(-6.7%) |
| Sep 1995 | - | $6.20M(-18.4%) | $28.40M(-8.7%) |
| Jun 1995 | - | $7.60M(+10.1%) | $31.10M(+14.8%) |
| Mar 1995 | - | $6.90M(-10.4%) | $27.10M(+16.8%) |
| Dec 1994 | $23.20M(+118.9%) | $7.70M(-13.5%) | $23.20M(+26.1%) |
| Sep 1994 | - | $8.90M(+147.2%) | $18.40M(+40.5%) |
| Jun 1994 | - | $3.60M(+20.0%) | $13.10M(+21.3%) |
| Mar 1994 | - | $3.00M(+3.4%) | $10.80M(+9.1%) |
| Dec 1993 | $10.60M(-7.8%) | $2.90M(-19.4%) | $9.90M(+6.5%) |
| Sep 1993 | - | $3.60M(+176.9%) | $9.30M(+14.8%) |
| Jun 1993 | - | $1.30M(-38.1%) | $8.10M(-19.0%) |
| Mar 1993 | - | $2.10M(-8.7%) | $10.00M(-12.3%) |
| Dec 1992 | $11.50M(+57.5%) | $2.30M(-4.2%) | $11.40M(+2.7%) |
| Sep 1992 | - | $2.40M(-25.0%) | $11.10M(+4.7%) |
| Jun 1992 | - | $3.20M(-8.6%) | $10.60M(+16.5%) |
| Mar 1992 | - | $3.50M(+75.0%) | $9.10M(+19.7%) |
| Dec 1991 | $7.30M(+46.0%) | $2.00M(+5.3%) | $7.60M(+10.1%) |
| Sep 1991 | - | $1.90M(+11.8%) | $6.90M(+9.5%) |
| Jun 1991 | - | $1.70M(-15.0%) | $6.30M(+8.6%) |
| Mar 1991 | - | $2.00M(+53.8%) | $5.80M(+16.0%) |
| Dec 1990 | $5.00M | $1.30M(0.0%) | $5.00M(+35.1%) |
| Sep 1990 | - | $1.30M(+8.3%) | $3.70M(+54.2%) |
| Jun 1990 | - | $1.20M(0.0%) | $2.40M(+100.0%) |
| Mar 1990 | - | $1.20M | $1.20M |
FAQ
- What is Regeneron Pharmaceuticals annual revenue?
- What is the all time high annual revenue for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual revenue year-on-year change?
- What is Regeneron Pharmaceuticals quarterly revenue?
- What is the all time high quarterly revenue for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly revenue year-on-year change?
- What is Regeneron Pharmaceuticals TTM revenue?
- What is the all time high TTM revenue for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM revenue year-on-year change?
What is Regeneron Pharmaceuticals annual revenue?
The current annual revenue of REGN is $14.20B
What is the all time high annual revenue for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual revenue is $16.07B
What is Regeneron Pharmaceuticals annual revenue year-on-year change?
Over the past year, REGN annual revenue has changed by +$1.08B (+8.27%)
What is Regeneron Pharmaceuticals quarterly revenue?
The current quarterly revenue of REGN is $3.79B
What is the all time high quarterly revenue for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly revenue is $5.14B
What is Regeneron Pharmaceuticals quarterly revenue year-on-year change?
Over the past year, REGN quarterly revenue has changed by +$354.90M (+10.33%)
What is Regeneron Pharmaceuticals TTM revenue?
The current TTM revenue of REGN is $14.20B
What is the all time high TTM revenue for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM revenue is $16.51B
What is Regeneron Pharmaceuticals TTM revenue year-on-year change?
Over the past year, REGN TTM revenue has changed by +$1.08B (+8.27%)